Bradykinin induces actin reorganization and enhances cell motility in HaCaT keratinocytes. 1997

K D Coutant, and N Corvaïa, and N S Ryder
Department of General Dermatology, NOVARTIS Research Institute, Brunner Strasse 59, Vienna, A-1235, Austria.

In HaCaT keratinocytes bradykinin-triggered actin reorganization was inhibited by quinacrine, a phospholipase A2 inhibitor, and restored by addition of arachidonic acid. Bradykinin-induced actin breakdown and cortical actin formation were respectively prevented by indomethacin, a cyclooxygenase inhibitor, and nordihydroguaiaretic acid, a lipoxygenase inhibitor. Addition of prostaglandins or leukotrienes, respectively, reversed the effects of inhibitors. This suggested a crucial role for a cyclooxygenase product in actin depolymerization and for a lipoxygenase product in cortical actin formation. Furthermore, we found that bradykinin stimulated HaCaT keratinocyte migration. This event was blocked by quinacrine, indomethacin or nordihydroguaiaretic acid, and restored by addition of prostaglandins or leukotrienes, respectively. We also showed that genistein, a tyrosine kinase inhibitor, inhibited HaCaT cell locomotion. In conclusion, bradykinin modulated actin reorganization and cell motility in keratinocytes, probably by a mechanism involving arachidonic acid metabolites and a tyrosine kinase activity.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D009637 Masoprocol A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils. Nordihydroguaiaretic Acid,(R*,S*)-4,4'-(2,3-Dimethylbutane-1,4-diyl)bispyrocatechol,Actinex,Dihydronorguaiaretic Acid,Nordihydroguaiaretic Acid, (R*,S*)-Isomer,meso-Nordihydroguaiaretic Acid,Acid, meso-Nordihydroguaiaretic,meso Nordihydroguaiaretic Acid
D010741 Phospholipases A Phospholipases that hydrolyze one of the acyl groups of phosphoglycerides or glycerophosphatidates.
D011796 Quinacrine An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2. Mepacrine,Acrichine,Atabrine,Atebrin,Quinacrine Dihydrochloride,Quinacrine Dihydrochloride, Dihydrate,Quinacrine Dihyrochloride, (R)-Isomer,Quinacrine Dihyrochloride, (S)-Isomer,Quinacrine Dimesylate,Quinacrine Hydrochloride,Quinacrine Monoacetate,Quinacrine Monohydrochloride,Quinacrine Monomesylate,Quinacrine, (+-)-Isomer,Quinacrine, (R)-Isomer,Quinacrine, (S)-Isomer,Dihydrochloride, Quinacrine,Dimesylate, Quinacrine,Hydrochloride, Quinacrine,Monoacetate, Quinacrine,Monohydrochloride, Quinacrine,Monomesylate, Quinacrine
D001920 Bradykinin A nonapeptide messenger that is enzymatically produced from KALLIDIN in the blood where it is a potent but short-lived agent of arteriolar dilation and increased capillary permeability. Bradykinin is also released from MAST CELLS during asthma attacks, from gut walls as a gastrointestinal vasodilator, from damaged tissues as a pain signal, and may be a neurotransmitter. Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg,Bradykinin Acetate, (9-D-Arg)-Isomer,Bradykinin Diacetate,Bradykinin Hydrochloride,Bradykinin Triacetate,Bradykinin, (1-D-Arg)-Isomer,Bradykinin, (2-D-Pro)-Isomer,Bradykinin, (2-D-Pro-3-D-Pro-7-D-Pro)-Isomer,Bradykinin, (2-D-Pro-7-D-Pro)-Isomer,Bradykinin, (3-D-Pro)-Isomer,Bradykinin, (3-D-Pro-7-D-Pro)-Isomer,Bradykinin, (5-D-Phe)-Isomer,Bradykinin, (5-D-Phe-8-D-Phe)-Isomer,Bradykinin, (6-D-Ser)-Isomer,Bradykinin, (7-D-Pro)-Isomer,Bradykinin, (8-D-Phe)-Isomer,Bradykinin, (9-D-Arg)-Isomer,Arg Pro Pro Gly Phe Ser Pro Phe Arg
D002461 Cell Line, Transformed Eukaryotic cell line obtained in a quiescent or stationary phase which undergoes conversion to a state of unregulated growth in culture, resembling an in vitro tumor. It occurs spontaneously or through interaction with viruses, oncogenes, radiation, or drugs/chemicals. Transformed Cell Line,Cell Lines, Transformed,Transformed Cell Lines
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000199 Actins Filamentous proteins that are the main constituent of the thin filaments of muscle fibers. The filaments (known also as filamentous or F-actin) can be dissociated into their globular subunits; each subunit is composed of a single polypeptide 375 amino acids long. This is known as globular or G-actin. In conjunction with MYOSINS, actin is responsible for the contraction and relaxation of muscle. F-Actin,G-Actin,Actin,Isoactin,N-Actin,alpha-Actin,alpha-Isoactin,beta-Actin,gamma-Actin,F Actin,G Actin,N Actin,alpha Actin,alpha Isoactin,beta Actin,gamma Actin

Related Publications

K D Coutant, and N Corvaïa, and N S Ryder
July 2005, Cancer science,
K D Coutant, and N Corvaïa, and N S Ryder
May 2005, Proceedings of the National Academy of Sciences of the United States of America,
K D Coutant, and N Corvaïa, and N S Ryder
May 2019, Pharmaceuticals (Basel, Switzerland),
K D Coutant, and N Corvaïa, and N S Ryder
November 2005, Medicinal chemistry (Shariqah (United Arab Emirates)),
K D Coutant, and N Corvaïa, and N S Ryder
January 1993, Archives of dermatological research,
K D Coutant, and N Corvaïa, and N S Ryder
August 2003, Experimental dermatology,
K D Coutant, and N Corvaïa, and N S Ryder
October 2003, The Journal of cell biology,
K D Coutant, and N Corvaïa, and N S Ryder
May 2016, International immunopharmacology,
Copied contents to your clipboard!